Scholarlink

<p>This study analyzed transcriptome sequencing data from rat samples, categorized into control (normal), model (chronic endometritis, CE), and test (treated with Penning Formula, PNF) groups, to identify key target genes of PNF in CE treatment and elucidate the specific mechanism of PNF treatment for CE. Differentially expressed genes (DEGs) between the model-control (DEGs1) and model-test (DEGs2) groups were compared, revealing 47 PNF-related genes (PRGs), primarily involved in stress response and prolactin signaling. These PRGs were cross-referenced with 909 target genes (TGs) of 25 active ingredients of PNF obtained from public databases, resulting in the identification of three key target genes: Bhmt, Scn10a, and Esr2. Further analysis, including functional pathway enrichment, chromosomal mapping, expression profiling, gene interactions, regulatory networks, and molecular docking, highlighted their involvement in stress response and prolactin signaling, with distinct chromosomal distributions and differential expression across groups. Additionally, miRNA predictions, such as rno-miR-29a-3p, were made, and significant binding interactions between key genes and active ingredients were observed. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) validation confirmed a marked down-regulation of Bhmt, Scn10a, and Esr2 in the treatment group, corroborating the therapeutic effect of PNF on CE. This study unveils novel targets and offers valuable insights into the mechanisms underlying PNF’s therapeutic action for CE.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification and validation of key target genes of penning formula for treating rat chronic endometritis model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Liu Zhihui,
  • Shi Jiani,
  • Chen Chen,
  • Yuan Yuqiong,
  • Chen Guorun,
  • Zhou Qianru

摘要

This study analyzed transcriptome sequencing data from rat samples, categorized into control (normal), model (chronic endometritis, CE), and test (treated with Penning Formula, PNF) groups, to identify key target genes of PNF in CE treatment and elucidate the specific mechanism of PNF treatment for CE. Differentially expressed genes (DEGs) between the model-control (DEGs1) and model-test (DEGs2) groups were compared, revealing 47 PNF-related genes (PRGs), primarily involved in stress response and prolactin signaling. These PRGs were cross-referenced with 909 target genes (TGs) of 25 active ingredients of PNF obtained from public databases, resulting in the identification of three key target genes: Bhmt, Scn10a, and Esr2. Further analysis, including functional pathway enrichment, chromosomal mapping, expression profiling, gene interactions, regulatory networks, and molecular docking, highlighted their involvement in stress response and prolactin signaling, with distinct chromosomal distributions and differential expression across groups. Additionally, miRNA predictions, such as rno-miR-29a-3p, were made, and significant binding interactions between key genes and active ingredients were observed. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) validation confirmed a marked down-regulation of Bhmt, Scn10a, and Esr2 in the treatment group, corroborating the therapeutic effect of PNF on CE. This study unveils novel targets and offers valuable insights into the mechanisms underlying PNF’s therapeutic action for CE.